The FDA Withdrew the Asbestos Testing Rule for Talc Cosmetics — Here Is What It Means for Your Talc Cancer Case
You used baby powder for years. Maybe decades. You used it the way millions of people did — after a shower, on your children, as part of a daily routine that felt safe because it was ordinary. Now you have an ovarian cancer diagnosis, or someone you love has mesothelioma, and you are sitting at a kitchen table at 2 a.m. reading that the FDA just pulled back the one rule that would have forced cosmetic companies to test their talc for asbestos. The question burning through your mind is simple: does this mean the companies get away with it?
No. It does not. And we will explain exactly why.
We are Attorney911 — The Manginello Law Firm. We handle toxic tort and catastrophic injury cases, including the kind of talc litigation that this FDA action touches. Ralph Manginello has spent 27-plus years in courtrooms, including federal court, and before he was a lawyer he was a journalist — which means he learned early that the story is never what the press release says, it is what the documents show. Lupe Peña spent years inside a national insurance-defense firm, in the rooms where adjusters and their software decided how to deny, delay, and devalue people exactly like you. He sat at their table. Now he sits at yours. He conducts full consultations in Spanish without an interpreter, and we say that with pride.
The FDA’s withdrawal of the proposed asbestos testing rule is not the end of your case. In some ways, it is the beginning of the argument. Here is what happened, what it means, and what to do about it.
What the FDA Actually Did on November 28, 2025 — and What It Did Not Do
On November 28, 2025, the FDA announced the withdrawal of its proposed rule titled “Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products.” That proposed rule had been published in the Federal Register on December 27, 2024. It was supposed to do something specific and important: establish standardized, mandatory testing methods that every manufacturer of talc-containing cosmetics would have to use to check their product for asbestos contamination before it reached a store shelf.
The FDA said it was withdrawing the rule because comments received during the public comment period “warrant further consideration and assessment prior to issuing final regulations.” In plain English: the agency tried to write a testing standard, the industry pushed back hard enough that the FDA pulled it back to reconsider, and now there is no rule.
What the FDA did NOT do is say talc is safe. What the FDA did NOT do is say asbestos contamination is not a concern. What the FDA did NOT do is fulfill the mandate Congress gave it.
In 2022, Congress passed the Modernization of Cosmetics Regulation Act — MoCRA. Section 3505 of that law specifically directed the FDA to establish and require standardized testing methods for detecting and identifying asbestos in talc-containing cosmetic products. That was a congressional mandate. The FDA’s withdrawal means that mandate remains unfulfilled. As of the FDA’s page content date of January 16, 2026, no mandatory federal asbestos testing standard for talc cosmetics exists.
That gap is not a technicality. It is the center of the legal argument.
“Cosmetic products and ingredients, with the exception of color additives, do not have to undergo FDA review or approval before they go on the market.”
— FDA, describing its own authority over cosmetics
That sentence, from the FDA’s own page, is the foundation of everything that follows. The federal government does not check cosmetic products before they reach you. The manufacturer self-certifies that the product is safe. And when it comes to asbestos in talc, the manufacturer was also the one deciding whether and how to test for it — because there was no federal standard forcing a particular method.
The Regulatory Vacuum: Why No Mandatory Testing Standard Exists
The Federal Food, Drug, and Cosmetic Act gives the FDA authority over cosmetic products, but that authority has a hole built into it. Unlike prescription drugs or medical devices, cosmetics do not go through premarket review or approval. The only exception is color additives. Everything else — the talc in baby powder, the talc in blush, the talc in body powder — enters the market on the manufacturer’s word that it is safe.
MoCRA was supposed to change part of this. For the first time in decades, Congress expanded the FDA’s oversight of cosmetics. Section 3505 specifically addressed asbestos in talc. Congress told the FDA: create a standard. Require testing. Make sure companies are checking for a known carcinogen in a product people put on their skin and breathe in every day.
The FDA proposed a rule in December 2024. The comment period opened. And then, eleven months later, the FDA withdrew it.
The FDA’s 2023 testing program tells you what the agency itself was finding. The FDA contracted with AMA Analytical Services to test talc-containing cosmetic products for asbestos using two laboratory methods: polarized light microscopy (PLM) and transmission electron microscopy (TEM). These are the same techniques a forensic mineralogist would use in a lawsuit to test a retained product container. The FDA selected products based on factors including product type, price range, social-media popularity, products marketed to children, and third-party reports of potential contamination. The results were published. They are publicly available.
That testing program is surveillance — the FDA checking the market after products are already on shelves. It is not pre-market gatekeeping. It is the government catching problems after consumers have already bought and used the product. And it is exactly the kind of after-the-fact checking that a mandatory testing standard would have made unnecessary, because the standard would have forced companies to catch the contamination before the product left the factory.
The withdrawal of the proposed rule means that surveillance, not prevention, remains the only federal approach. The regulatory vacuum that existed before MoCRA — the one Congress tried to fill — is still there.
Talc and Asbestos: Why They Show Up Together
This is not a mystery. It is geology.
Talc is a naturally occurring mineral — hydrous magnesium silicate, mined from the earth. Asbestos is also a naturally occurring silicate mineral, with a different crystal structure. The two form under similar geological conditions and are frequently found in close proximity in the same mineral deposits. When you mine talc, you can get asbestos with it. Not always, but often enough that the FDA has been raising the concern since the 1970s.
“Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth.”
— FDA
The FDA’s own page says that “it is important to select talc mining sites carefully and take steps to test the ore sufficiently.” That is the agency telling you the solution: mine from clean deposits, test the ore, keep asbestos out of the product. The problem is that without a mandatory federal testing standard, each manufacturer decides for itself what “carefully” and “sufficiently” mean. And the FDA’s withdrawal of the proposed rule means there is still no federal definition of what adequate testing looks like.
This is where the design-defect theory in talc litigation live. The argument is not just that a particular batch was contaminated. The argument is that talc deposits geologically co-occur with asbestos, making contamination foreseeable, and that a product whose raw material inherently carries a known carcinogen is unreasonably dangerous by design — especially when safer alternatives (cornstarch-based powders) exist and have existed for years.
The Science: Talc and Ovarian Cancer (1960s to Now)
The FDA’s own page acknowledges what the scientific literature has been saying for more than half a century:
“Published scientific literature going back to the 1960s has suggested a possible association between the use of powders containing talc in the genital area and the incidence of ovarian cancer.”
The FDA also notes that “these studies have not conclusively demonstrated such a link” and that “more research is needed to confirm if there is a link or not.”
That framing — “possible association” but “not conclusively demonstrated” — is exactly where the legal fight lives. The defense will point to the FDA’s hedged language and say: even the government is not sure. The plaintiff’s response is: the government has been studying this since the 1960s and still has not ruled it out. When an association persists across six decades of research, the absence of a definitive conclusion is not evidence of safety. It is evidence of an unresolved danger that a manufacturer knew about and did not warn the consumer about.
The mechanism matters. When talc powder is applied in the perineal/genital area — as baby powder and body powder have been used for generations — particles can migrate upward through the reproductive tract. Talc particles have been found in ovarian tissue. The proposed biological mechanism involves chronic inflammation from foreign particles in the ovarian epithelium, which over years and decades can drive cellular changes that lead to cancer. The latency is long. A woman who used talc daily in her twenties and thirties may not receive an ovarian cancer diagnosis until her fifties or sixties.
That latency is both the medical reality and the legal challenge. The defense exploits the gap between exposure and diagnosis to argue that intervening factors — genetics, environment, other exposures — broke the chain of causation. The plaintiff’s answer is the discovery rule: the clock to file a lawsuit often does not start on the day you used the product. It starts on the day you were diagnosed — or the day you reasonably should have connected your diagnosis to talc exposure. More on that below, because it is one of the most important deadlines in your case.
The Science: Asbestos Contamination and Mesothelioma
The second category of talc injury is different, and in some ways more straightforward.
When talc is contaminated with asbestos and a person inhales the powder, they are breathing in asbestos fibers. Asbestos is classified by the International Agency for Research on Cancer as a Group 1 carcinogen — the highest category, reserved for substances where the evidence of cancer-causing potential in humans is sufficient. This is not disputed. The defense cannot argue about whether asbestos causes cancer. It is settled science.
Mesothelioma is a cancer of the lining of the lungs (the pleura) or, less commonly, the abdomen. It is essentially signature to asbestos exposure — so much so that a mesothelioma diagnosis is itself near-conclusive evidence of significant asbestos exposure somewhere in the person’s history. The latency is extraordinary: typically 20 to 50 years, most commonly 30 to 40 years, between first exposure and diagnosis. A person who used asbestos-contaminated talc products in their teens and twenties may not develop mesothelioma until their sixties or seventies.
The mechanism is physical. Inhaled asbestos fibers are durable — the same properties that made asbestos useful industrially are what make it lethal biologically. The fibers lodge in the pleural lining. The body cannot break them down or clear them. Over decades, the chronic physical irritation and the chemical effects of the fibers drive malignant transformation of the mesothelial cells. The fibers are still there, in the tissue, when the cancer appears — which is why a mineralogist can sometimes find asbestos fibers in a biopsy specimen and trace them back to the product.
This is where product identification becomes critical. If you have a retained container of the talc product you used — an old bottle of baby powder, a container of body powder, a compact of blush — a forensic mineralogist can test the remaining powder using TEM and PLM, the same methods the FDA used in its 2023 survey. If asbestos fibers are found in the product, that is product-specific proof of contamination — not a general argument about the industry, but evidence that the specific product you used contained the specific carcinogen that caused your specific cancer.
That is why the first instruction we give anyone who calls is: do not throw away any old product containers. Secure them. Put them in a zip-top bag and store them. They may be the single most important piece of physical evidence in your case.
Who Is Responsible: The Defendant Structure in Talc Litigation
A talc case is rarely about one defendant. It is about a chain — and understanding that chain is the difference between a case that recovers and a case that runs dry.
The first tier is the cosmetic product manufacturer — the company that designed the product, formulated it, marketed it, and put it on the shelf. This is the entity whose name is on the bottle. For decades, the dominant defendant in talc litigation has been Johnson & Johnson, through its consumer subsidiary Johnson & Johnson Consumer Inc. But the manufacturer landscape extends to other companies that produced talc-containing cosmetics — from baby powder to pressed powders to blush to body powders sold under dozens of brand names.
The J&J talc docket is the largest in the country. As of June 1, 2026, the federal multi-district litigation — MDL-2738, In re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation — had 68,029 actions pending before Judge Michael A. Shipp in the District of New Jersey. That number tells you the scale: this is not a handful of lawsuits. It is tens of thousands of women and families who say the same product caused the same harm.
J&J has fought these cases with a strategy that has become its own chapter in mass-tort history. Three times, J&J attempted to wall off its talc liability inside a shell entity and push that entity into bankruptcy — a maneuver sometimes called the “Texas two-step.” The first attempt used LTL Management LLC. The second used the same vehicle. The third used Red River Talc LLC. On March 31, 2025, the U.S. Bankruptcy Court for the Southern District of Texas — Judge Christopher Lopez — denied confirmation and dismissed Red River Talc’s prepackaged Chapter 11. The court found vote-solicitation irregularities and impermissible nonconsensual third-party releases. Three attempts. Three failures. The cases are back in the tort system, where they belong.
If you have heard that J&J “went bankrupt” and there is no money to recover, that is the opposite of what happened. The bankruptcy court refused to let them use bankruptcy that way. The cases continue.
The second tier is the talc supplier and mining company — the entity that extracted the talc ore, processed it, and sold it to the manufacturer. The duty at this level is to select mining sites carefully and test the ore sufficiently — the exact duty the FDA describes on its own page. If a supplier shipped asbestos-contaminated talc to a manufacturer without disclosing the contamination, the supplier is a separate defendant with its own liability.
The third tier is the retailer and distributor — the stores and online platforms that sold the product to you. Under chain-of-distribution liability principles, entities in the stream of commerce can bear responsibility for selling a defective or dangerous product.
The fourth tier — where it exists — is the testing and certification laboratory. If a laboratory provided certifications that a talc product was asbestos-free, and that certification was false, misleading, or methodologically deficient, the laboratory can face liability. This is where the FDA’s withdrawal of the testing rule becomes especially relevant: without a federal standard, what testing method is “adequate” becomes a battleground, and a lab that certified a product using a method that misses asbestos fibers (for example, using only PLM when TEM is necessary to detect the finest fibers) may have provided a false certification.
The Evidence Clock: What Exists, Who Holds It, and How Fast It Disappears
Every talc case lives or dies on evidence. The problem is that the most important evidence is also the most fragile — and much of it has been disappearing on a clock that started long before you knew you had a case.
Retained product containers and unused talc powder samples. These are the crown jewels of a talc case. A forensic mineralogist can test the remaining powder in an old bottle of baby powder for asbestos fibers using TEM and PLM — the same methodology the FDA used in its 2023 testing program. If the product tests positive for asbestos, you have product-specific proof that the specific item you used was contaminated. Product containers get discarded during household cleanouts, relocations, estate dispersals after a death, or simply because nobody thought they mattered. If you have any old containers, secure them immediately. If a family member who has passed away used talc products, check their belongings before the estate is dispersed. Those bottles are evidence.
Purchase receipts, pharmacy records, and subscription/delivery histories. These establish how long you used the product, how often you bought it, and in what volume. Duration and frequency of use are central to specific causation and dose reconstruction. Retailers purge transaction records on rolling schedules. Loyalty-program data may become inaccessible after an account is closed. Subscription delivery records (auto-ship programs, recurring online orders) can be pulled but only if requested within the provider’s retention window — often 12 to 18 months. If your talc use stretched over decades, the most recent purchase records are the most retrievable. The older ones may already be gone.
Medical records — pathology reports, tumor biomarker profiles, and treatment histories. These document the cancer diagnosis, the histological subtype, the staging, the treatment course, and the prognosis. They are the foundation of damages quantification and specific causation. HIPAA generally requires healthcare providers to retain records for six years, but obtaining complete records early avoids provider mergers, record-system migrations, and the gaps that appear when a treating physician has retired or passed away. The pathology report in particular is non-negotiable — it documents the specific cancer subtype, which matters enormously for causation.
Sworn usage-history statements from family members and household contacts. For a product you used for decades, the corroboration of a spouse, adult child, sibling, or roommate who remembers the brand, the frequency, the application method, and the years of use is often the only available exposure evidence. Legacy products may no longer exist on any shelf. Memories degrade. Elderly family members may pass. Memorializing this testimony through recorded statements or affidavits promptly — while memories are sharp and witnesses are available — is something we prioritize from the day a case opens.
Corporate discovery targets. Once a case is in litigation, the discovery process forces the manufacturer to produce internal documents: asbestos testing results, supplier quality-control correspondence, safety committee minutes, regulatory affairs communications, and marketing materials. These are the documents that build the punitive-damages narrative — proof that the company knew about asbestos contamination risks, knew about the ovarian cancer association, and made choices about what to tell consumers and what to keep internal. Document retention policies may permit destruction on rolling schedules. Litigation holds — formal demands that the company preserve documents — must be issued early in discovery to prevent spoliation.
FDA testing data and AMA Analytical Services reports. The FDA’s 2023 testing results are publicly available. They include a summary table listing product distributor/manufacturer, brand, product name, batch/lot number, FDA sample ID, and findings. These publicly available results can support both general causation (asbestos contamination in talc cosmetics is a documented reality) and product-specific causation (if the product you used was among those tested and found contaminated). These reports are already published and accessible — lower urgency, but should be catalogued and analyzed early for product identification matches.
The Medicine: What Talc-Related Cancer Looks Like and How It Is Proven
Talc litigation involves two distinct disease categories, and they demand different proof.
Ovarian Cancer from Perineal Talc Use
The mechanism: talc particles applied to the perineal area migrate through the reproductive tract to the ovaries. The body cannot break down talc — it is a mineral. The particles persist in the ovarian tissue, causing chronic inflammation. Over years and decades, that inflammation can drive the cellular changes that lead to epithelial ovarian cancer.
The diagnostics: ovarian cancer is typically diagnosed through imaging (ultrasound, CT), tumor markers (CA-125), and ultimately surgical exploration with biopsy and pathology. The pathology report identifies the histological subtype — serous, endometrioid, clear cell, mucinous — which matters for causation because some subtypes are more strongly associated with inflammatory pathways than others. Treatment typically involves surgical intervention — debulking surgery, oophorectomy (removal of ovaries), often hysterectomy — followed by chemotherapy regimens. Radiation therapy may be used in selected cases. Recurrence monitoring continues for years, and many ovarian cancer patients face recurrence.
The proof problem the defense exploits: ovarian cancer has multiple known risk factors — genetics (BRCA mutations), family history, reproductive history, hormone use, obesity, endometriosis. The defense argues that this particular cancer came from one of those factors, not from talc. The plaintiff’s counter is dose and duration: a woman who used talc daily for thirty years in the genital area has a cumulative exposure that the epidemiological literature has associated with elevated ovarian cancer risk, and the defense’s alternative explanations must be ruled out through differential diagnosis by a qualified oncologist.
The damages: past and future medical expenses, surgical costs, chemotherapy costs, lost wages, diminished earning capacity, life-care planning for ongoing monitoring and potential recurrence, pain and suffering, loss of enjoyment of life, loss of consortium. In fatal cases, wrongful death recovery for surviving beneficiaries — which includes the financial support the deceased would have provided, the services they performed, and in many jurisdictions, the companionship and guidance the family lost.
Mesothelioma from Asbestos-Contaminated Talc
The mechanism: asbestos fibers in contaminated talc are inhaled during product use. The fibers lodge in the pleura — the lining of the lungs — or in the peritoneum. The body cannot clear them. Over 20 to 50 years, the fibers cause chronic inflammation and cellular damage that can lead to malignant mesothelioma. The fiber’s durability is what makes it lethal — the same resistance to heat and chemical breakdown that made asbestos industrially useful is what prevents the body from eliminating it.
The diagnostics: imaging (CT, PET), pleural biopsy with immunohistochemistry to distinguish mesothelioma from adenocarcinoma, and occupational/exposure history. The exposure history is itself diagnostic-grade evidence — because mesothelioma is so specifically tied to asbestos, identifying the source of exposure is part of the medical workup.
The proof problem: attribution. The defense argues the asbestos exposure came from somewhere else — an old job, a family member’s work clothes, a building renovation, automotive brake work. The plaintiff’s counter is product identification: if the specific talc product the plaintiff used is shown (through TEM/PLM testing of a retained sample) to contain asbestos, and the plaintiff’s exposure history does not include other significant asbestos sources, the product becomes the identified cause. Co-worker testimony, family testimony, and household exposure reconstruction by an industrial hygienist fill the gap.
The damages: mesothelioma carries a grim prognosis — median survival is often measured in months to a few years. Treatment includes aggressive oncological intervention (surgery, chemotherapy, immunotherapy, radiation), but the disease is almost always fatal. The damages are therefore dominated by pain and suffering, the emotional terror of a terminal diagnosis, lost earning capacity (often a full career cut short), and in fatal cases, wrongful death. The compressed timeline between diagnosis and death makes the survival-action component — the victim’s own pain, suffering, and awareness of impending death — particularly significant.
What a Talc Case Is Worth — Honest Numbers
We do not promise outcomes. We do promise honesty about what these cases are worth, based on the landscape of verdicts and settlements that has developed over years of litigation.
Individual talc litigation matters vary enormously. Based on the case type, the injury, the jurisdiction, the defendant, and the strength of causation evidence, individual case values range from approximately $1,500,000 on the low end to $40,000,000 or more on the high end.
The factors that drive value up: mesothelioma cases with confirmed asbestos contamination in retained product samples and documented exposure histories tend toward the upper range, particularly in jurisdictions that permit substantial punitive damages. Ovarian cancer cases in plaintiff-favorable venues have produced significant verdicts. Punitive damages are a major value driver where plaintiffs can demonstrate manufacturer knowledge of asbestos contamination risks dating to the 1970s and inadequate testing or concealment of internal findings.
The factors that pull value down: ovarian cancer claims face more contested general causation than mesothelioma claims — the scientific association is there but not as definitive as the asbestos-mesothelioma link. Defendant bankruptcy proceedings (even failed ones) affect recovery timelines and settlement value. Comparative-fault arguments about consumer choice appear in some jurisdictions. And jurisdictional damage caps in tort-reform states can limit non-economic recovery.
The anchor verdict that most talc attorneys look to is Ingham v. Johnson & Johnson. In July 2018, a Missouri jury returned a verdict of $4.69 billion for 22 women who claimed talc caused their ovarian cancer. On appeal, the Missouri Court of Appeals reduced that to approximately $2.12 billion. The Missouri Supreme Court denied review. On June 1, 2021, the United States Supreme Court denied certiorari — meaning the reduced award stood. That is the number that matters: approximately $2.1 billion, affirmed, certiorari denied. The original $4.69 billion was cut roughly in half, and that reduced figure is the one the highest court in the country let stand.
Past results depend on the facts of each case and do not guarantee future outcomes.
That sentence is not a disclaimer we put in fine print. It is the truth. Your case is not Ingham. It has its own facts, its own defendant, its own jurisdiction, its own jury pool. What the Ingham verdict tells you is that juries, when presented with the evidence, have been willing to assign enormous value to the harm talc caused. What it does not tell you is what your case will produce. That depends on the work done to build it.
For a deeper look at how case value is calculated, including the economic and human-loss components that go into a demand, Ralph has recorded a detailed explanation on how much a personal injury case is worth that walks through the methodology our forensic economists and life-care planners use.
The Defense Playbook: What the Other Side Will Try
The companies that manufactured and sold talc products have been defending these cases for years. They have a playbook. Knowing it in advance is your armor.
Play 1: “The science is not settled.” The defense will point to the FDA’s own hedged language — “possible association,” “not conclusively demonstrated” — and argue that the causal link between talc and ovarian cancer is unproven. They will hire epidemiologists to testify that the studies are flawed, the association is weak, and your cancer came from something else. The counter is the accumulated weight of six decades of research, the biological plausibility of the mechanism, the presence of talc particles in ovarian tissue in published studies, and differential diagnosis by your treating oncologist ruling out alternative causes. The defense does not need to win the science argument — they need to create doubt. Our job is to make the science clear enough that doubt is not reasonable.
Play 2: “You chose to use the product.” Comparative fault and consumer-choice arguments appear in some jurisdictions. The defense argues that consumers knew or should have known about potential risks and chose to use the product anyway. The counter is the failure-to-warn theory: the manufacturer had internal knowledge of asbestos contamination risks and the ovarian cancer association and did not put adequate warnings on the product. A consumer cannot make an informed choice about a risk they were never told about. The FDA’s own page acknowledges that the association has been studied since the 1960s — the question is whether the manufacturer shared that information with the people buying the powder.
Play 3: “The bankruptcy shield.” J&J’s three attempts to use bankruptcy to wall off talc liability have all failed — but the strategy itself is a play. The companies may argue that recovery must come through a bankruptcy trust, at reduced values and on a payment schedule, rather than through individual tort litigation. The counter is that the bankruptcy courts have refused to allow this maneuver, the cases are in the tort system, and your right to a jury trial in the appropriate jurisdiction is intact. If anyone — a claims administrator, a bankruptcy trustee, a company representative — contacts you about filing a claim in a bankruptcy proceeding, do not sign anything, do not file anything, and do not make any statement before you speak with qualified toxic tort counsel.
Play 4: “The clock ran out.” The defense will examine when you were diagnosed and when you first learned talc might be connected to your cancer. In many jurisdictions, the statute of limitations for toxic tort cases runs from the date of discovery — the date you knew or reasonably should have known that your injury was connected to the exposure. The defense will argue you knew earlier than you say and the deadline has passed. The counter depends on the specific jurisdiction’s discovery-rule formulation and the facts of when the connection between your diagnosis and talc was made — by you, by your doctor, or by the media coverage that brought the association to public attention.
Play 5: “It was a different exposure.” Especially in mesothelioma cases, the defense will argue your asbestos exposure came from somewhere other than talc — a job site, a family member, a building, automotive work. The counter is product-specific evidence (retained product testing positive for asbestos), a thorough exposure reconstruction by an industrial hygienist that rules out other significant sources, and the medical reality that mesothelioma’s long latency means the exposure could have been a product you used daily for years without thinking about it.
The Proof Story: How a Talc Case Is Actually Built
Here is the chronological walk of how a talc case is assembled, from the first phone call through resolution.
Week one. The preservation letter goes out. If you have retained product containers, they are secured and photographed. If you do not, we document what brands you used, for how long, and how you used them. Medical records are requested — pathology reports, treatment histories, imaging, tumor markers. Family members who can corroborate your usage history are identified and their statements are memorialized. This is the evidence-gathering sprint, and it happens before any lawsuit is filed because the evidence is perishable.
Pre-suit investigation. The retained product, if one exists, is sent to a forensic mineralogist for TEM and PLM analysis. The FDA’s 2023 testing data is reviewed for matches to products you used. Your medical records are reviewed by an oncologist to confirm diagnosis, subtype, staging, and to begin the differential diagnosis that will support specific causation. An epidemiologist is identified to address general causation — the question of whether talc can cause ovarian cancer (or whether asbestos in talc can cause mesothelioma) in the scientific literature.
Filing. The complaint is filed in the jurisdiction that best fits the facts — which may be the state where you live, where you were exposed, where the defendant is incorporated, or where an MDL is centralized. Venue selection in mass tort is strategic and depends on the specific laws, jury pools, and procedural rules of each potential forum. The FD&C Act’s lack of premarket review for cosmetics means there is no federal preemption defense like the one that exists for FDA-approved drugs or PMA medical devices. The regulatory vacuum that the FDA’s withdrawal just highlighted actually helps the plaintiff’s case on failure-to-warn theories: the absence of a federal standard means there is no federal shield for the manufacturer to hide behind.
Discovery. This is where the corporate documents come out. The manufacturer is compelled to produce internal testing results, supplier communications, safety committee minutes, regulatory affairs filings, and marketing materials. The documents that matter most are the ones showing what the company knew about asbestos contamination and the ovarian cancer association, when they knew it, and what they chose to do (or not do) about it. These documents are the engine of punitive damages — they transform the case from “a product was contaminated” to “a company knew about the danger and made a choice.”
Expert depositions. The epidemiologist testifies on general causation. The mineralogist testifies on the TEM/PLM findings and the geological reality of talc-asbestos co-occurrence. The oncologist testifies on specific causation — why this cancer, in this patient, is attributable to this exposure. The industrial hygienist testifies on exposure reconstruction — how much talc this person likely inhaled or applied over how many years. The defense’s experts are deposed too, and the gaps in their methodology are exposed.
Resolution. Most cases resolve through settlement, either individually or as part of a larger resolution framework. Some go to trial. The bellwether trials in the MDL — the test cases that go before a jury to establish what the evidence looks like and what a jury does with it — shape the settlement value of the thousands of cases behind them. The Ingham verdict ($4.69 billion reduced to ~$2.12 billion, affirmed) is the most prominent bellwether outcome in the talc ovarian cancer docket.
Your First Steps: What to Do Now and What Not to Do
If you used talc-containing body powders or cosmetic products and you have been diagnosed with ovarian cancer or mesothelioma — or if someone you love used these products and has passed away from cancer — there are specific steps to take and specific traps to avoid.
Do secure any remaining product containers. Old bottles of baby powder, body powder, or cosmetic talc products are physical evidence. Do not discard them. Do not open and use them. Place them in sealed bags and store them safely. If a family member who used talc products has passed away, check their personal belongings before the estate is dispersed. Those containers can be tested for asbestos contamination and may provide product-specific proof that ties your case to a specific manufacturer’s product.
Do gather your medical records. Request complete copies of your medical file — pathology reports, imaging studies, treatment records, physician notes. HIPAA gives you the right to your records. Get them now, while they are complete and while providers still have them. Provider mergers, record-system migrations, and physician retirements create gaps that widen over time.
Do document your usage history. Write down everything you can remember about your talc use — which brands, which products, how often you used them, how many years, the method of application. Ask family members and household contacts to do the same. The decades-long use pattern that is central to your case is proven through your own testimony and the corroboration of people who lived with you. Memories fade. Write it down now.
Do confirm the deadline for your state. The statute of limitations that governs your claim depends on where you live, where the exposure occurred, and where the case may be filed. In many jurisdictions, the clock for toxic tort claims runs from the date of discovery — the date you knew or should have known that your cancer was connected to talc exposure. Some states measure from the date of diagnosis. Some have statutes of repose that impose an outer deadline regardless of discovery. These deadlines are unforgiving and they are short — typically two to three years from the triggering date, though some states allow longer. You must confirm the specific deadline for your jurisdiction with qualified counsel without delay. Do not assume you have plenty of time. Do not assume the clock started on the day you used the product — it may have started on the day you were diagnosed. But do not assume that either. Confirm it.
Do not communicate with manufacturer representatives, insurance adjusters, or bankruptcy claims administrators. If someone contacts you — by phone, by mail, by email — claiming to represent the company, offering to help, asking you to sign a form, asking you to record a statement, or telling you about a claims process: stop. Do not sign anything. Do not make any statement. Do not file anything. Call a lawyer first. The documents they send you are designed to limit the company’s liability, not to help you. A release you sign today can extinguish your right to sue forever.
Do not post about your case on social media. Defense investigators monitor social media. Posts about your health, your activities, your daily life, and your emotional state can be taken out of context and used to undermine your damages claim. The safest approach is to say nothing about your case, your diagnosis, or your legal situation online until your case is resolved.
Do not wait. Evidence disappears. Witnesses pass away. Product containers get thrown out. Records get purged. The single most important thing you can do is act. Not next month. Not after treatment is over. Not after you feel better. Now.
The FDA Withdrawal and Your Legal Rights: The Double-Edged Sword
The FDA’s withdrawal of the proposed asbestos testing rule is strategically significant for talc litigation, and it cuts both ways.
For plaintiffs, the withdrawal is powerful support for failure-to-warn theories. Congress passed a law — MoCRA section 3505 — specifically directing the FDA to create a testing standard. The FDA proposed one. The industry’s comments were substantial enough that the FDA pulled the rule back. The result is that the MoCRA mandate is unfulfilled and no mandatory federal testing standard exists. The argument is straightforward: the regulatory gap that Congress tried to close is still open, and it persisted throughout the decades that consumers were using these products without warnings. The absence of a federal standard does not excuse the manufacturer — it highlights the manufacturer’s own failure to adopt adequate testing voluntarily.
For the defense, the withdrawal offers a counter-narrative: the FDA pulled the rule because the scientific community disagrees about which testing methods are appropriate and reliable. The defense will argue that the withdrawal reflects genuine scientific uncertainty, not industry obstruction. They will say: if the government’s own experts cannot agree on a testing method, how can a jury conclude that a manufacturer’s testing was inadequate?
Both arguments have force. The outcome depends on the specific facts of your case, the jurisdiction, and the quality of the expert testimony on both sides. What the withdrawal definitively does is keep the regulatory landscape exactly where it has been for decades: no mandatory premarket testing, no federal standard for asbestos detection in talc cosmetics, and post-market surveillance as the only federal check. For anyone who used these products during the decades that this vacuum existed, that landscape is the backdrop of their case.
The Firm: Who Fights for You
Ralph Manginello has been licensed to practice law since November 6, 1998 — 27-plus years. He is admitted to the United States District Court for the Southern District of Texas, including its Bankruptcy Court, which means he can litigate in federal court — where many mass tort cases, including the talc MDL, are filed. Before he was a lawyer, Ralph was a journalist. That training is not a footnote. It is the reason the first thing we do in any case is go find the documents that tell the real story — not the press release, not the company’s safety brochure, not the FDA’s hedged public statement, but the internal testing memos, the supplier correspondence, and the safety-committee minutes that show what the company knew and when it knew it. Ralph is a member of the Texas Trial Lawyers Association, the Houston Bar Association, the National Association of Criminal Defense Lawyers, and the Pro Bono College of the State Bar of Texas.
Lupe Peña has been licensed since December 6, 2012. Before he joined this firm, Lupe worked inside a national insurance-defense firm — the rooms where adjusters and their valuation software (programs like Colossus) decide how to price, delay, and deny claims. He knows how the other side sets reserves in the first 48 hours after an incident. He knows how they select IME doctors. He knows the recorded-statement script that is engineered to get you to say “I’m feeling okay” on tape before your MRI results come back. He knows because he used to run those plays. Now he uses that knowledge for injured clients. Lupe is fluent in Spanish and conducts full client consultations in Spanish without an interpreter. He is a third-generation Texan with family roots tracing to the King Ranch.
We work on contingency. That means we do not get paid unless we win your case. The fee is 33.33 percent of the recovery before trial and 40 percent if the case goes to trial. Your first consultation is free. We have live staff available 24 hours a day, 7 days a week — not an answering service. When you call, you reach a person. If you want to understand how contingency fees work in detail, Ralph has recorded a plain-language explanation of contingency fee structures that walks through exactly what you pay and when.
If your family has lost someone to cancer and you are considering a wrongful death claim, the deadlines are often shorter than for survival claims, and estate administration deadlines may further constrain your ability to file. Family members of individuals who used talc products and have since passed away should act with particular urgency.
Frequently Asked Questions
Does the FDA’s withdrawal of the asbestos testing rule mean I can’t sue?
No. The FDA’s withdrawal of the proposed testing rule does not eliminate your legal rights. It does not grant immunity to manufacturers. It does not change the statutes of limitations that govern your claim. What it does is highlight the regulatory vacuum that existed throughout the period you were using these products — a vacuum that supports failure-to-warn claims by showing there was no federal standard requiring companies to test for asbestos, and no federal warning requirement informing consumers of the risk.
I used baby powder for years and was diagnosed with ovarian cancer. Do I have a case?
You may. Whether you have a viable claim depends on several factors: the specific products you used, the duration and frequency of use, the method of application, your medical history and whether alternative causes of your ovarian cancer can be ruled out, whether you have retained product containers, and the statute of limitations in your jurisdiction. The only way to know is to speak with qualified counsel who can evaluate your specific facts. The consultation is free.
How long do I have to file a talc lawsuit?
The deadline depends on your state. In many jurisdictions, the statute of limitations for toxic tort claims is measured from the date of discovery — the date you knew or should have known that your cancer was connected to your talc use. This may be the date of diagnosis, the date a doctor first mentioned the connection, or the date you learned about it through media coverage. Some states have statutes of repose that impose an outer deadline. These deadlines are typically two to three years from the triggering event, though some states allow more or less time. This is not something to guess about. The deadline for your specific situation must be confirmed with counsel in your jurisdiction immediately.
I have mesothelioma but I never worked with asbestos. Could it be from talc?
It is possible. Mesothelioma is caused by asbestos exposure, and asbestos has been found as a contaminant in talc products. If you used talc-containing cosmetics or body powders over a period of years and do not have other significant known asbestos exposure sources (occupational, household, environmental), contaminated talc products are a potential source. A thorough exposure reconstruction by an industrial hygienist, combined with testing of any retained product containers, can help identify the source. Mesothelioma’s long latency — often 30 to 40 years — means the exposure could have occurred during a period of your life you may not immediately connect to the diagnosis.
What if I don’t have the original product containers anymore?
Not having retained product containers does not automatically end your case, but it makes it harder. Product-specific testing of a retained container is the strongest form of product identification evidence. Without it, we rely on your sworn usage history, corroborating testimony from family members, purchase records (if retrievable), and the FDA’s published testing data that may identify specific products and lots found to be contaminated. In ovarian cancer cases, product identification is often based on usage history rather than physical product testing. In mesothelioma cases, product-specific asbestos identification is more important, and the absence of a retained container is a greater challenge.
Johnson & Johnson filed for bankruptcy. Is there any money left to recover?
J&J’s bankruptcy strategy failed three times. The most recent attempt — Red River Talc LLC’s prepackaged Chapter 11 — was dismissed by the U.S. Bankruptcy Court for the Southern District of Texas on March 31, 2025. The court found vote-solicitation irregularities and impermissible nonconsensual third-party releases. The cases are back in the tort system. J&J has not successfully used bankruptcy to wall off its talc liability. The more than 68,000 cases pending in the federal MDL as of June 2026 are proceeding in the regular court system.
Will I have to go to trial?
Most talc cases resolve through settlement rather than trial. But the strength of your settlement position depends on the willingness and ability to take the case to trial. A case that is built for trial — with retained expert witnesses, preserved evidence, and a documented corporate-knowledge narrative — settles from a position of strength. A case that is built only for settlement settles from a position of weakness. We build every case as if it will be tried.
How much does it cost to hire a talc lawyer?
Nothing upfront. We work on contingency — 33.33 percent of the recovery before trial, 40 percent if the case goes to trial. We do not get paid unless we win your case. The initial consultation is free, confidential, and carries no obligation. You can reach us at 1-888-ATTY-911 — 1-888-288-9911 — 24 hours a day, 7 days a week. You will reach a live person, not a recording.
Can I still file a claim if the person who used the talc products has already passed away?
Yes, but the deadlines are different and often shorter. A wrongful death claim is brought by the surviving family members or the personal representative of the estate. A survival action belongs to the estate and covers the harm the deceased suffered between injury and death. Both have their own statutes of limitations, which vary by state. Wrongful death limitations periods are often shorter than survival claim periods. Estate administration deadlines may further constrain filing. If your family member used talc products and died of ovarian cancer or mesothelioma, you should contact counsel urgently to determine what claims survive and what deadlines apply.
Is the FDA’s withdrawal of the testing rule good or bad for my case?
It is strategically double-edged. For plaintiffs, the withdrawal supports failure-to-warn claims by highlighting the absence of a mandatory federal testing standard — which means the manufacturer cannot argue it complied with a federal requirement. The unfulfilled MoCRA mandate shows that Congress recognized the danger and the industry resisted accountability. For the defense, the withdrawal offers an argument that scientific disagreement about testing methodology — not industry obstruction — drove the decision. How this plays out depends on your jurisdiction, your judge, and the quality of expert testimony. In our assessment, the withdrawal is more helpful than harmful to plaintiffs overall, because it keeps the regulatory landscape exactly where it was during the period of exposure: a vacuum with no mandatory standard and no premarket gatekeeping.
I’m not sure I can prove which specific product I used. Does that matter?
It matters, but it may not be dispositive. In ovarian cancer cases, proof of talc use often relies on the plaintiff’s own testimony about which brands they used, corroborated by family members, rather than on physical product containers. The defense will challenge product identification, but a credible, consistent usage history — especially when corroborated — can be sufficient. In mesothelioma cases, product identification is more important because the defense will argue other asbestos sources. Having a retained product container that tests positive for asbestos is the strongest form of product identification, but it is not the only path. Do not assume your case is too weak because you lack physical product. Call and let us evaluate what you do have.
What to Do Right Now
If you have read this far, you are not browsing. You are deciding whether to act. Here is what we need you to do.
Call 1-888-ATTY-911. That is 1-888-288-9911. The call is free. The consultation is free. You will speak with a live person, not an answering service, at any hour of any day. If you prefer, you can reach Ralph directly at ralph@atty911.com or Lupe at lupe@atty911.com. Or contact us through our website.
If you speak Spanish, we serve your family fully in Spanish. Lupe Peña conducts complete consultations in Spanish without an interpreter. Hablamos Español.
Before you call, gather what you can: any old product containers, any medical records you already have, and a written summary of which talc products you used, for how many years, and how you used them. If you do not have all of that, call anyway. We can help you gather it.
Do not talk to the company. Do not sign anything from the company. Do not file anything in a bankruptcy proceeding without speaking to us first. Do not post about your diagnosis or your case on social media.
The FDA withdrew the testing rule. Congress’s mandate is unfulfilled. The regulatory vacuum that let these products reach you without testing is the same vacuum your case can shine a light into. The companies knew. The science has been there since the 1960s. The asbestos concerns have been there since the 1970s. What happened to you was not an accident and it was not a mystery. It was a choice — by manufacturers who could have tested, could have warned, and did not.
That is what we go find. That is what we prove. And we do not get paid unless we win your case.
Call us. 1-888-ATTY-911. Today.